PLXProtalix BioTherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Protalix BioTherapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLXThis | $209M#3 | 11.3x#2 | 2.9x#4 | 4.0x#2 | -1.2%#2 | -325.2%#6 | -10.4%#1 | -9.2%#1 | -12.3%#1 | 3#1 | 9.3%#3 | — |
| ALEC | $230M#1 | — | — | 10.9x#4 | -79.1%#4 | -20.2%#3 | -741.3%#5 | — | — | — | 42.1%#2 | — |
| PALI | $216M#2 | 1.9x#1 | 1.8x#3 | — | — | -16.2%#2 | — | -13.8%#2 | — | — | — | — |
| IKT | $208M#4 | — | 1.4x#2 | — | -100.0%#5 | -75.4%#5 | — | -31.5%#4 | — | — | — | — |
| DTIL | $194M#5 | 21.7x#3 | 3.7x#6 | 5.7x#3 | -50.1%#3 | -738.0%#7 | -152.2%#3 | -88.3%#6 | — | — | -6.1%#4 | — |
| ACOG | $180M#6 | — | 3.4x#5 | 17.6x#5 | — | -39.8%#4 | -221.7%#4 | -39.0%#5 | — | — | 44.0%#1 | — |
| IVVD | $172M#7 | — | 1.0x#1 | 3.2x#1 | 110.5%#1 | 69.1%#1 | -104.0%#2 | -29.0%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice